Curcumin chemoprevention reduces the incidence of BRAF-mutant colorectal cancer in a preclinical study

被引：0
|
作者：
Kane, A. [1 ,2 ,5 ]
Liu, C. [1 ,2 ,7 ]
Akhter, D. [3 ]
Mckeone, D. [1 ]
Bell, C. [3 ]
Thurecht, K. [3 ,4 ]
Leggett, B. [1 ,2 ,6 ]
Whitehall, V. [1 ,2 ,5 ]
机构：
[1] Univ Queensland, QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia
[2] Univ Queensland, Fac Med, Brisbane, Qld, Australia
[3] Univ Queensland, Ctr Adv Imaging, Australian Inst Bioengn & Nanotechnol, ARC Ctr Excellence Bio Nano Sci & Technol, Brisbane, Qld, Australia
[4] Univ Queensland, ARC Training Ctr Innovat Biomed Imaging Technol, Brisbane, Qld, Australia
[5] Pathol Queensland, Conjoint Internal Med Lab, Brisbane, Qld, Australia
[6] Queensland Hlth, Royal Brisbane & Womens Hosp, Dept Gastroenterol & Hepatol, Brisbane, Qld, Australia
[7] Envoi Specialist Pathologists, Brisbane, Qld, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2020年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
303
引用
收藏
页码：162 / 163
页数：2
相关论文
共 50 条
  • [1] Curcumin Chemoprevention Reduces the Incidence of Braf Mutant Colorectal Cancer in a Preclinical Study
    Kane, Alexandra M.
    Liu, Cheng
    Akhter, Dewan T.
    McKeone, Diane M.
    Bell, Craig A.
    Thurecht, Kristofer J.
    Leggett, Barbara A.
    Whitehall, Vicki L. J.
    DIGESTIVE DISEASES AND SCIENCES, 2021, 66 (12) : 4326 - 4332
  • [2] Curcumin Chemoprevention Reduces the Incidence of Braf Mutant Colorectal Cancer in a Preclinical Study
    Alexandra M. Kane
    Cheng Liu
    Dewan T. Akhter
    Diane M. McKeone
    Craig A. Bell
    Kristofer J. Thurecht
    Barbara A. Leggett
    Vicki L. J. Whitehall
    Digestive Diseases and Sciences, 2021, 66 : 4326 - 4332
  • [3] Aspirin reduces the incidence of metastasis in a preclinical study of Braf mutant colorectal cancer
    Kane, Alexandra
    Liu, Cheng
    Fennell, Lochlan
    McKeone, Diane
    Borowsky, Jennifer
    Leggett, Barbara
    Whitehall, Vicki
    CANCER RESEARCH, 2020, 80 (16)
  • [4] Preclinical efficacy of carfilzomib in BRAF-mutant colorectal cancer models
    Maione, Federica
    Oddo, Daniele
    Galvagno, Federica
    Falcomata, Chiara
    Pandini, Marta
    Macagno, Marco
    Pessei, Valeria
    Barault, Ludovic
    Gigliotti, Chiara
    Mira, Alessia
    Corti, Giorgio
    Lamba, Simona
    Riganti, Chiara
    Castella, Barbara
    Massaia, Massimo
    Rad, Roland
    Saur, Dieter
    Bardelli, Alberto
    Di Nicolantonio, Federica
    MOLECULAR ONCOLOGY, 2024, 18 (06) : 1552 - 1570
  • [5] Aspirin reduces the incidence of metastatic Braf mutant colorectal cancer in a preclinical trial
    Kane, A.
    Mckeone, D.
    Liu, C.
    Borowsky, J.
    Leggett, B.
    Whitehall, V.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 33 - 33
  • [6] Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer
    Yang, Hong
    Higgins, Brian
    Kolinsky, Kenneth
    Packman, Kathryn
    Bradley, William D.
    Lee, Richard J.
    Schostack, Kathleen
    Simcox, Mary Ellen
    Kopetz, Scott
    Heimbrook, David
    Lestini, Brian
    Bollag, Gideon
    Su, Fei
    CANCER RESEARCH, 2012, 72 (03) : 779 - 789
  • [7] Hitting the Target in BRAF-Mutant Colorectal Cancer
    Nagaraja, Ankur K.
    Bass, Adam J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) : 3990 - +
  • [8] Targeted therapy for BRAF-mutant colorectal cancer
    Gunjur, Ashray
    LANCET ONCOLOGY, 2019, 20 (11): : E618 - E618
  • [9] Management of BRAF-mutant metastatic colorectal cancer
    Burge, Matthew
    Whitehall, Vicki
    COLORECTAL CANCER, 2016, 5 (04) : 131 - 133
  • [10] Molecular targeted therapy of BRAF-mutant colorectal cancer
    Ducreux, Michel
    Chamseddine, Ali
    Laurent-Puig, Pierre
    Smolenschi, Cristina
    Hollebecque, Antoine
    Dartigues, Peggy
    Samallin, Emmanuelle
    Boige, Valerie
    Malka, David
    Gelli, Maximiliano
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
12345